AU2022235091A1 - Methods and compositions for treatment of disease - Google Patents

Methods and compositions for treatment of disease Download PDF

Info

Publication number
AU2022235091A1
AU2022235091A1 AU2022235091A AU2022235091A AU2022235091A1 AU 2022235091 A1 AU2022235091 A1 AU 2022235091A1 AU 2022235091 A AU2022235091 A AU 2022235091A AU 2022235091 A AU2022235091 A AU 2022235091A AU 2022235091 A1 AU2022235091 A1 AU 2022235091A1
Authority
AU
Australia
Prior art keywords
abatacept
aldesleukin
administered
formulation
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022235091A
Other languages
English (en)
Other versions
AU2022235091A9 (en
Inventor
Stanley Hersh APPEL
Howard Berman
Alireza FARIDAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Methodist Hospital
Coya Therapeutics Inc
Original Assignee
Methodist Hospital
Coya Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methodist Hospital, Coya Therapeutics Inc filed Critical Methodist Hospital
Publication of AU2022235091A1 publication Critical patent/AU2022235091A1/en
Publication of AU2022235091A9 publication Critical patent/AU2022235091A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36082—Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Developmental Disabilities (AREA)
  • Psychology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2022235091A 2021-03-11 2022-03-10 Methods and compositions for treatment of disease Pending AU2022235091A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163159919P 2021-03-11 2021-03-11
US63/159,919 2021-03-11
US202163225846P 2021-07-26 2021-07-26
US63/225,846 2021-07-26
US202263310839P 2022-02-16 2022-02-16
US63/310,839 2022-02-16
PCT/US2022/019748 WO2022192536A1 (en) 2021-03-11 2022-03-10 Methods and compositions for treatment of disease

Publications (2)

Publication Number Publication Date
AU2022235091A1 true AU2022235091A1 (en) 2023-09-21
AU2022235091A9 AU2022235091A9 (en) 2023-10-12

Family

ID=83228307

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022235091A Pending AU2022235091A1 (en) 2021-03-11 2022-03-10 Methods and compositions for treatment of disease

Country Status (8)

Country Link
US (1) US20240148827A1 (https=)
EP (1) EP4304624A4 (https=)
JP (1) JP2024509911A (https=)
KR (1) KR20230169147A (https=)
AU (1) AU2022235091A1 (https=)
CA (1) CA3211627A1 (https=)
MX (1) MX2023010455A (https=)
WO (1) WO2022192536A1 (https=)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
EP1878440A1 (en) * 2006-07-13 2008-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds
WO2008127298A2 (en) * 2006-10-24 2008-10-23 Subroto Chatterjee Staphylococcal enterotoxin b peptide compositions and methods of use
US9044459B2 (en) * 2008-12-05 2015-06-02 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
EP2367849B1 (en) * 2008-12-05 2017-11-01 ALS Therapy Development Institute Method for the treatment of neurodegenerative diseases
CN102573500A (zh) * 2009-08-06 2012-07-11 纽拉尔图斯制药公司 巨噬细胞相关疾病的治疗
PL3053932T3 (pl) * 2010-02-19 2021-03-08 Xencor, Inc. Nowe immunoadhezyny CTLA4-IG
KR102220006B1 (ko) * 2011-03-11 2021-02-24 아시스땅스 퍼블리끄-오삐또 드 빠리 자가면역 - 관련 또는 염증성 장애를 치료하기 위한 저용량 ｉｌ­２ 의 용도
EP2734232B1 (en) * 2011-07-19 2017-11-01 Philogen S.p.A. Sequential anti-ctla4 and targeted il-2 therapy
WO2013041029A1 (en) * 2011-09-23 2013-03-28 Igenimed Pharmaceuticals Inc. Novel soluble ctla4 variants
US20140044675A1 (en) * 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
WO2014206899A1 (en) * 2013-06-25 2014-12-31 Icm (Institut Du Cerveau Et De La Moelle Épinière) Boosting treg cells for treating alzheimer disease and related disorders
US20170233485A1 (en) * 2014-08-18 2017-08-17 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
EP3192805A1 (en) * 2016-01-15 2017-07-19 Humanitas Mirasole S.p.A. Inhibitors of t cell activation or stimulation and uses thereof
JP7181862B2 (ja) * 2016-10-18 2022-12-01 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 腫瘍浸潤リンパ球および治療の方法
US11077172B2 (en) * 2016-11-08 2021-08-03 Delinia, Inc. IL-2 variants for the treatment of psoriasis
CA3103603A1 (en) * 2018-06-13 2019-12-19 Akron Biotechnology, LLC. Method to prepare therapeutically active aldesleukin highly stable in liquid pharmaceutical compositions
JP2022510377A (ja) * 2018-12-03 2022-01-26 デルマタ・セラピューティクス，エルエルシー 状態の処置のための組成物
CN113795271A (zh) * 2019-03-08 2021-12-14 森德治疗公司 与irgd共施用以治疗癌症的低剂量细胞因子
CN109999179A (zh) * 2019-05-08 2019-07-12 山东省分析测试中心 低剂量白介素2用于制备治疗阿尔茨海默病药物中的应用

Also Published As

Publication number Publication date
EP4304624A1 (en) 2024-01-17
US20240148827A1 (en) 2024-05-09
MX2023010455A (es) 2023-11-28
EP4304624A4 (en) 2025-02-19
AU2022235091A9 (en) 2023-10-12
WO2022192536A1 (en) 2022-09-15
JP2024509911A (ja) 2024-03-05
KR20230169147A (ko) 2023-12-15
CA3211627A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
ES2436616T5 (es) Formulaciones proteicas estables
AU2008212004B2 (en) Method for the treatment of multiple sclerosis
ES2783448T3 (es) Métodos de tratamiento del lupus eritematoso sistémico utilizando un anticuerpo de dominio dirigido contra CD28
CN108026175A (zh) 用于治疗癫痫的方法
EP4716698A1 (en) Treatment of multiple sclerosis with anti-cd40l antibodies
SK281806B6 (sk) Použitie il-10 na prípravu liečiva na prevenciu diabetes mellitus
WO2021126637A1 (en) Methods of treating pancytopenia
KR20210087045A (ko) 재생불량성 빈혈을 치료하기 위한 의약 조성물
US20240148827A1 (en) Methods and Compositions for Treatment of Disease
CN117337189A (zh) 用于治疗疾病的方法和组合物
CN115243673A (zh) 阵发性睡眠性血红蛋白尿症的治疗
US10071134B2 (en) Therapeutic uses of CD137pos regulatory T cells
US20250049934A1 (en) DOSING REGIMENS FOR SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS
WO2026030323A1 (en) Methods and compositions for treatment of disease
WO2026030328A1 (en) Methods and compositions for treatment of disease
WO2026030334A1 (en) Methods and compositions for treatment of disease
HK40082135A (en) Treatment of paroxysmal nocturnal hemoglobinuria
HK1114568B (en) Stable protein formulations

Legal Events

Date Code Title Description
SREP Specification republished